B7-H3 Inhibitors in Oncology Clinical Trials: A Review
Authors:
Open Access
- 1 February 2024
- journal article
- review article
- Published by Innovative Healthcare Institute in Journal of Immunotherapy and Precision Oncology
- Vol. 7 (1) , 53-66
Abstract
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. There are clinical trials on the horizon that have not yet enrolled patients examining chimeric antigen receptor T-cell therapies, bi- and tri-specific killer engagers, and dual-affinity retargeting proteins. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.Keywords
This publication has 55 references indexed in Scilit:
- Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3Journal of Biological Chemistry, 2015
- ILT4 drives B7‐H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7‐H3 co‐expression correlates with poor prognosis in non‐small cell lung cancerFEBS Letters, 2015
- Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3Structure, 2013
- B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 PhosphorylationMolecular Cancer Therapeutics, 2011
- 4IgB7‐H3 is the major isoform expressed on immunocytes as well as malignant cellsTissue Antigens, 2007
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T CellsThe Journal of Immunology, 2004
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Characterization of Mouse and Human B7-H3 GenesThe Journal of Immunology, 2002
- B7-H3: A costimulatory molecule for T cell activation and IFN-γ productionNature Immunology, 2001